The influence of supplemental sodium acetate on carbonic anhydrase inhibitor-induced side effects.
A double-masked, randomly assigned, crossover trial of the effect of supplemental two-weak courses of sodium acetate (90 mEq/day) and placebo on carbonic anhydrase inhibitor (CAI)-induced side effects of malaise, fatigue, and others ("malaise symptom complex") was performed in 28 patients. Fifteen patients (54%) experienced significant improvement while receiving supplemental sodium acetate compared with five (18%) receiving a placebo. A relationship was observed between the clinical efficacy of the acetate supplementation and the measured improvement in serum carbon dioxide combining power. No changes in intraocular pressure were observed when supplemental sodium acetate was given. The results confirm the beneficial effect of supplemental alkalinization for such CAI-induced symptoms in somewhat less than half of the affected patients and suggest the need for long-term studies in which the dosage of sodium acetate is titrated in relation to measured changes in the level of metabolic acidosis.
D000085:Acetates / Q000627:therapeutic use*; D000138:Acidosis / Q000139:chemically induced / Q000188:drug therapy; D000328:Adult; D000368:Aged; D002245:Carbon Dioxide / Q000097:blood; D002257:Carbonic Anhydrase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D002712:Chlorides / Q000097:blood; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005221:Fatigue / Q000139:chemically induced / Q000188:drug therapy; D005260:Female; D005901:Glaucoma / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos
D000085:Acetates; D002257:Carbonic Anhydrase Inhibitors; D002712:Chlorides; D010919:Placebos; D002245:Carbon Dioxide